

## DAFTAR PUSTAKA

- Abdelbagi, O., Musa, I.R., Musa, S.M., AlTigani, S.A., Adam, I., 2021. Prevalence and associated factors of hypertension among adults with diabetes mellitus in northern Sudan: a cross-sectional study. *BMC Cardiovasc. Disord.* 21, 1–7. <https://doi.org/10.1186/S12872-021-01983-X/TABLES/3>
- ADA, 2021. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. *Diabetes Care* 44, S15 LP-S33. <https://doi.org/10.2337/dc21-S002>
- Adeniyi, O.V., Yogeswaran, P., Longo-Mbenza, B., Goon, D. Ter, 2016. Uncontrolled Hypertension and Its Determinants in Patients with Concomitant Type 2 Diabetes Mellitus (T2DM) in Rural South Africa. *PLoS One* 11, e0150033. <https://doi.org/10.1371/JOURNAL.PONE.0150033>
- Ahn, E., Kang, H., 2018. Introduction to systematic review and meta-analysis. *Korean J. Anesthesiol.* 71, 103–112. <https://doi.org/10.4097/kjae.2018.71.2.103>
- Akalu, Y., Belsti, Y., 2020a. Hypertension and its associated factors among type 2 diabetes mellitus patients at Debre Tabor general hospital, northwest Ethiopia. *Diabetes, Metab. Syndr. Obes. Targets Ther.* 13, 1621–1631. <https://doi.org/10.2147/DMSO.S254537>
- Akalu, Y., Belsti, Y., 2020b. Hypertension and Its Associated Factors Among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia. *Diabetes, Metab. Syndr. Obes. Targets Ther.* 13, 1621–1631. <https://doi.org/10.2147/DMSO.S254537>
- Almalki, Z.S., Albassam, A.A., Alhejji, N.S., Alotaibi, B.S., Al-Oqayli, L.A., Ahmed, N.J., 2020. Prevalence, risk factors, and management of uncontrolled hypertension among patients with diabetes: A hospital-based cross-sectional study. *Prim. Care Diabetes* 14, 610–615. <https://doi.org/10.1016/J.PCD.2020.02.004>
- Almobarak, A.O., Badi, S., Siddiq, S.B., Noor, S.M., Elmadhoun, W.M., Suliman,

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITOR TERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- M., Ahmed, M.H., 2020. The prevalence and risk factors for systemic hypertension among Sudanese patients with diabetes mellitus: A survey in diabetes healthcare facility. *Diabetes Metab. Syndr. Clin. Res. Rev.* 14, 1607–1611. <https://doi.org/10.1016/J.DSX.2020.08.010>
- American Heart Association, 2017. Know Your Risk Factors for High Blood Pressure | American Heart Association [WWW Document]. URL <https://www.heart.org/en/health-topics/high-blood-pressure/why-high-blood-pressure-is-a-silent-killer/know-your-risk-factors-for-high-blood-pressure> (accessed 12.29.21).
- Association, A.D., 2020. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020. *Diabetes Care* 43, S111–S134. <https://doi.org/10.2337/DC20-S010>
- Bae, J., Park, E., Kim, S, Kim, SG, ... S.H.-E. and, 2021, undefined, n.d. Comparative renal effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2. *ncbi.nlm.nih.gov*.
- Bae, J.H., Park, E.-G., Kim, S., Kim, S.G., Hahn, S., Kim, N.H., 2019. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <https://doi.org/10.1038/s41598-019-49525-y>
- Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., Broedl, U.C., 2014. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. *lancet. Diabetes Endocrinol.* 2, 369–384. [https://doi.org/10.1016/S2213-8587\(13\)70208-0](https://doi.org/10.1016/S2213-8587(13)70208-0)
- Belanger, M.J., Hill, M.A., Angelidi, A.M., Dalamaga, M., Sowers, J.R., Mantzoros, C.S., 2020. Covid-19 and Disparities in Nutrition and Obesity. *N. Engl. J. Med.* 383, e69. [https://doi.org/10.1056/NEJMP2021264/SUPPL\\_FILE/NEJMP2021264\\_DI SCLOSURES.PDF](https://doi.org/10.1056/NEJMP2021264/SUPPL_FILE/NEJMP2021264_DI SCLOSURES.PDF)

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITORTERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- CDC, 2021. Put the Brakes on Diabetes Complications | DDT [WWW Document]. Centers Dis. Control Prev. URL <https://www.cdc.gov/diabetes/library/features/prevent-complications.html> (accessed 12.26.21).
- CDC, 2020. National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States.
- Chrysant, S.G., 2017. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: A new class of antidiabetic drugs. *Drugs of Today* 53, 191–202. <https://doi.org/10.1358/DOT.2017.53.3.2555985>
- Cowie, M.R., Fisher, M., 2020. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. *Nat. Rev. Cardiol.* 17, 761–772. <https://doi.org/10.1038/s41569-020-0406-8>
- De Boer, I.H., Bangalore, S., Benetos, A., Davis, A.M., Michos, E.D., Muntner, P., Rossing, P., Zoungas, S., Bakris, G., 2017. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. *Diabetes Care* 40, 1273–1284. <https://doi.org/10.2337/DCI17-0026>
- Dharma Pathni, P.M.S., 2019. Terapi Diabetes dengan SGLT-2 Inhibitor. *Cermin Dunia Kedokt.* 46, 452–456.
- FDA, 2018. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors | FDA [WWW Document]. Food Drug Adm. URL <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/sodium-glucose-cotransporter-2-sgl2-inhibitors> (accessed 12.8.21).
- FDA, 2013. Story of Discovery: SGLT2 inhibitors: harnessing the kidneys to help treat diabetes | NIDDK [WWW Document]. URL <https://www.niddk.nih.gov/news/archive/2016/story-discovery-sgl2-inhibitors-harnessing-kidneys-help-treat-diabetes> (accessed 5.15.22).
- Garcia-Ropero, A., Badimon, J.J., Santos-Gallego, C.G., 2018. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. *Expert Opin. Drug Metab. Toxicol.* 14, 1287–1302. <https://doi.org/10.1080/17425255.2018.1551877>
- Gerdts, E., Regitz-Zagrosek, V., 2019. Sex differences in cardiometabolic

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITOR TERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- disorders. *Nat. Med.* 2019 2511 25, 1657–1666.  
<https://doi.org/10.1038/s41591-019-0643-8>
- Goyal, R., Jialal, I., 2021. *Diabetes Mellitus Type 2*. StatPearls Publishing, Treasure Island.
- Hill, M.A., Yang, Y., Zhang, L., Sun, Z., Jia, G., Parrish, A.R., Sowers, J.R., 2021. Insulin resistance, cardiovascular stiffening and cardiovascular disease. *Metab. - Clin. Exp.* 119. <https://doi.org/10.1016/J.METABOL.2021.154766>
- Hsia, D.S., Grove, O., Cefalu, W.T., 2017. An Update on SGLT2 Inhibitors for the Treatment of Diabetes Mellitus. *Curr. Opin. Endocrinol. Diabetes. Obes.* 24, 73. <https://doi.org/10.1097/MED.0000000000000311>
- IDF, 2020. *Complications* [WWW Document]. URL <https://www.idf.org/aboutdiabetes/complications.html> (accessed 12.10.21).
- James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., Lackland, D.T., Lefevre, M.L., Mackenzie, T.D., Ogedegbe, O., Smith, S.C., Svetkey, L.P., Taler, S.J., Townsend, R.R., Wright, J.T., Narva, A.S., Ortiz, ; Eduardo, 2014. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) Clinical Review & Education Special Communication 507. *JAMA* 311, 507–520. <https://doi.org/10.1001/jama.2013.284427>
- JB1, 2020. CHECKLIST FOR SYSTEMATIC REVIEWS AND RESEARCH SYNTHESSES Critical Appraisal tools for use in JBI Systematic Reviews.
- Kalumpiu, J.V., 2019. Dapagliflozin : manfaat dan risiko pada diabetes melitus tipe 2. *J. Biomedika dan Kesehatan.* 2, 81–89. <https://doi.org/10.18051/jbiomedkes.2019.v2.81-89>
- Kario, K., Ferdinand, K.C., O’Keefe, J.H., 2020. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. *Prog. Cardiovasc. Dis.* 63, 249–262. <https://doi.org/10.1016/J.PCAD.2020.04.003>
- Kemche, B., Ulrich, B., Foudjo, S., Fokou, E., 2020. Risk Factors of Hypertension among Diabetic Patients from Yaoundé Central Hospital and Etoug-Ebe Baptist Health 2020.

- Lin, Y.P., 2013. Albuminuria in hypertension. *Hypertens. Res.* 2013 369 36, 762–764. <https://doi.org/10.1038/hr.2013.76>
- Moses, R.G., Colagiuri, S., Pollock, C., 2014. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. *undefined* 7, 405–415. <https://doi.org/10.4066/AMJ.2014.2181>
- Naha, S., Gardner, M.J., Khangura, D., Kurukulasuriya, L.R., Sowers, J.R., 2021. Hypertension in Diabetes, Endotext. MDText.com, Inc.
- Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondou, N., Shaw, W., Law, G., Desai, M., Matthews, D.R., 2017. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N. Engl. J. Med.* 377, 644–657. <https://doi.org/10.1056/NEJMOA1611925>
- Nelinson, D.S., Sosa, J.M., Chilton, R.J., 2021. SglT2 inhibitors: A narrative review of efficacy and safety. *J. Am. Osteopath. Assoc.* 121, 229–239. <https://doi.org/10.1515/JOM-2020-0153/MACHINEREADABLECITATION/RIS>
- Oliva, R. V., Bakris, G.L., 2014. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. *J. Am. Soc. Hypertens.* 8, 330–339. <https://doi.org/10.1016/J.JASH.2014.02.003>
- Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., Zuñiga, F.A., 2018. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc. Diabetol.* 2018 171 17, 1–14. <https://doi.org/10.1186/S12933-018-0762-4>
- Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw, J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S., McGuinness, L.A., Stewart, L.A., Thomas, J., Tricco, A.C., Welch, V.A., Whiting, P., Moher, D., 2021. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 372, 2020–2021. <https://doi.org/10.1136/bmj.n71>
- Passarella, P., Kiseleva, T.A., Valeeva, F. V., Gosmanov, A.R., 2018. Hypertension Management in Diabetes: 2018 Update. *Diabetes Spectr.* 31,

- 218–224. <https://doi.org/10.2337/DS17-0085>
- Pati, D., Lorusso, L.N., 2018. How to Write a Systematic Review of the Literature. *Heal. Environ. Res. Des. J.* 11, 15–30. <https://doi.org/10.1177/1937586717747384>
- PERKENI, 2019. Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2019. PB PERKENI.
- Persson, F., Bain, S.C., Mosenzon, O., Heerspink, H.J.L., Mann, J.F.E., Pratley, R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B.J., Rossing, P., 2021. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. *Diabetes Care* 44, 1020–1026. <https://doi.org/10.2337/DC20-1622>
- Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M.E., Tsapas, A., Karagiannis, A., 2019. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. *J. Hypertens.* 37, 1334–1343. <https://doi.org/10.1097/HJH.0000000000002050>
- Prohic, N., Rosivall, L., Remuzzi, G., Coppolino, G., Provenzano, M., De Nicola, L., Serra, R., Garofalo, C., Andreucci, M., Bolignano, D., 2019. Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale. <https://doi.org/10.3389/fcell.2019.00314>
- Rai, R.K., Kumar, C., Singh, P.K., Singh, L., Barik, A., Chowdhury, A., 2020. Incidence of Prehypertension and Hypertension in Rural India, 2012–2018: A Sex-Stratified Population-Based Prospective Cohort Study. *Am. J. Hypertens.* 33, 552–562. <https://doi.org/10.1093/AJH/HPAA034>
- Reilly, R., Evans, K., Gomersall, J., Gorham, G., Peters, M.D.J., Warren, S., O’Shea, R., Cass, A., Brown, A., 2016. Effectiveness, cost effectiveness, acceptability and implementation barriers/enablers of chronic kidney disease management programs for Indigenous people in Australia, New Zealand and Canada: a systematic review of mixed evidence. *BMC Health Serv. Res.* 16. <https://doi.org/10.1186/S12913-016-1363-0>
- RMIT, 2021. Synthesise - Systematic Reviews - All guides at RMIT University

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITORTERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- [WWW Document]. RMIT Univ. Libr. URL <https://rmit.libguides.com/c.php?g=724535&p=5386370> (accessed 12.29.21).
- Ruggenti, P., Remuzzi, G., 2019. Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research. *Am J Nephrol* 49, 143–145. <https://doi.org/10.1159/000496275>
- Russo, B., Menduni, M., Borboni, P., Picconi, F., Frontoni, S., 2021. Autonomic Nervous System in Obesity and Insulin-Resistance—The Complex Interplay between Leptin and Central Nervous System. *Int. J. Mol. Sci.* 2021, Vol. 22, Page 5187 22, 5187. <https://doi.org/10.3390/IJMS22105187>
- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A.A., Ogurtsova, K., Shaw, J.E., Bright, D., Williams, R., 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* 157. <https://doi.org/10.1016/J.DIABRES.2019.107843>
- Sapra, A., Bhandari, P., 2021. Diabetes Mellitus, StatPearls. StatPearls Publishing, Treasure Island.
- Sauri, I., Uso, R., Trillo, J.L., Fernandez, A., Holgado, J.L., Lopez, C., Vela, S., Bea, C., Ruiz, A., Martinez, F., Redon, J., 2021. IMPACT OF HYPERTENSION IN THE MORBIDITY AND MORTALITY IN DIABETES MELLITUS: A REAL-WORLD DATA. *J. Hypertens.* 39, e23. <https://doi.org/10.1097/01.HJH.0000744592.58414.72>
- Schmidt, L., Olorisade, B.K., Mcguinness, L.A., Thomas, J., Higgins, J.P.T., Mcfarlane, E., Kaiser, K.A., Del Carmen, M., Prieto, A., 2021. Data extraction methods for systematic review (semi)automation: A living systematic review. *F1000Research* 2021 10401 10, 401. <https://doi.org/10.12688/f1000research.51117.1>
- Shahoud, J.S., Sanvictores, T., Aeddula, N.R., 2020. Physiology, Arterial Pressure Regulation, StatPearls. StatPearls Publishing, Treasure Island.
- Shaikh, A., 2017. A Practical Approach to Hypertension Management in

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITORTERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

- Diabetes. *Diabetes Ther.* 8, 981–989. <https://doi.org/10.1007/s13300-017-0310-3>
- Townsend, R.R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., Pfeifer, M., 2016. Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension. *J. Clin. Hypertens. (Greenwich)*. 18, 43–52. <https://doi.org/10.1111/JCH.12747>
- Tsimihodimos, V., Gonzalez-Villalpando, C., Meigs, J.B., Ferrannini, E., 2018. Hypertension and Diabetes Mellitus Coprediction and Time Trajectories. *Hypertension* 71, 422–428. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10546>
- Unger, T., Borghi, C., Charchar, F., Khan, N.A., Poulter, N.R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G.S., Tomaszewski, M., Wainford, R.D., Williams, B., Schutte, A.E., 2020. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension* 75, 1334–1357. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15026>
- Vachek, J., Zakiyanov, O., Tesar, V., 2021. Proteinuria, *Interni Medicina pro Praxi*. StatPearls Publishing. <https://doi.org/10.1177/1755738019894027>
- Waly, E.H., Hamed, M.S., 2018. Hypertension and Dyslipidemia among Type II Diabetic Patients and Related Risk Factors and Complications. *Egypt. J. Community Med.* 36.
- Wang, Z., Yang, T., Fu, H., 2021. Prevalence of diabetes and hypertension and their interaction effects on cardio-cerebrovascular diseases: a cross-sectional study. *BMC Public Health* 21, 1224. <https://doi.org/10.1186/S12889-021-11122-Y/TABLES/7>
- Weber, M.A., Mansfield, T.A., Alessi, F., Iqbal, N., Parikh, S., Ptaszynska, A., 2016. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. *Blood Press.* 25, 93–103. <https://doi.org/10.3109/08037051.2015.1116258>
- Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E., Collins, K.J., Himmelfarb, C.D., DePalma, S.M., Gidding, S., Jamerson, K.A., Jones,



- D.W., MacLaughlin, E.J., Muntner, P., Ovbiagele, B., Smith, S.C., Spencer, C.C., Stafford, R.S., Taler, S.J., Thomas, R.J., Williams, K.A., Williamson, J.D., Wright, J.T., Levine, G.N., O’Gara, P.T., Halperin, J.L., Past, I., Al, S.M., Beckman, J.A., Birtcher, K.K., Bozkurt, B., Brindis, R.G., Cigarroa, J.E., Curtis, L.H., Deswal, A., Fleisher, L.A., Gentile, F., Goldberger, Z.D., Hlatky, M.A., Ikonomidis, J., Joglar, J.A., Mauri, L., Pressler, S.J., Riegel, B., Wijeyesundera, D.N., Walsh, M.N., Jacobovitz, S., Oetgen, W.J., Elma, M.A., Scholtz, A., Sheehan, K.A., Abdullah, A.R., Tahir, N., Warner, J.J., Brown, N., Robertson, R.M., Whitman, G.R., Hundley, J., 2018. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines. *Hypertension* 71, E13–E115. <https://doi.org/10.1161/HYP.000000000000065/-/DC2>
- Wilcox, C.S., 2020. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. *Hypertension* 894–901. <https://doi.org/10.1161/HYPERTENSIONAHA.119.11684>
- Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., Silverman, M.G., Zelniker, T.A., Kuder, J.F., Murphy, S.A., Bhatt, D.L., Leiter, L.A., McGuire, D.K., Wilding, J.P.H., Ruff, C.T., Gause-Nilsson, I.A.M., Fredriksson, M., Johansson, P.A., Langkilde, A.-M., Sabatine, M.S., 2019. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N. Engl. J. Med.* 380, 347–357. <https://doi.org/10.1056/NEJM0A1812389>
- World Health Organization, 2021. Hypertension [WWW Document]. World Heal. Organ. URL <https://www.who.int/news-room/fact-sheets/detail/hypertension> (accessed 11.22.21).
- World Health Organization, 2020. The top 10 causes of death [WWW Document]. World Heal. Organ. URL <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (accessed 12.10.21).
- Wright, E., 2021. SGLT2 Inhibitors: Physiology and Pharmacology.

**Fatimah Azzahra, 2022**

**PENGARUH SGLT-2 INHIBITORTERHADAP TEKANAN DARAH DAN ALBUMINURIA PADA PASIEN DIABETES MELITUS TIPE 2 DENGAN HIPERTENSI: TELAAH SISTEMATIK**

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana  
[[www.upnvj.ac.id](http://www.upnvj.ac.id) – [www.library.upnvj.ac.id](http://www.library.upnvj.ac.id) – [www.repository.upnvj.ac.id](http://www.repository.upnvj.ac.id)]

<https://doi.org/10.34067/KID.0002772021>

- Wulandari, V., Trusda, S.A.D., Nilapsari, R., 2021. Scoping Review SGLT-2 Inhibitor Efektif dalam Menurunkan Albuminuria pada Pasien Diabetes Melitus Tipe 2. *J. Integr. Kesehat. Sains* 3, 65–71. <https://doi.org/10.29313/jiks.v3i1.7478>
- Yale, J.F., Bakris, G., Cariou, B., Yue, D., David-Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., Meininger, G., 2013. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. *Diabetes. Obes. Metab.* 15, 463–473. <https://doi.org/10.1111/DOM.12090>
- Ye, N., Jardine, M.J., Oshima, M., Hockham, C., Heerspink, H.J.L., Agarwal, R., Bakris, G., Schutte, A.E., Arnott, C., Chang, T.I., Górriz, J.L., Cannon, C.P., Charytan, D.M., De Zeeuw, D., Levin, A., Mahaffey, K.W., Neal, B., Pollock, C., Wheeler, D.C., Luca Di Tanna, G., Cheng, H., Perkovic, V., Neuen, B.L., 2021. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial. *Circulation* 143, 1735–1749. <https://doi.org/10.1161/CIRCULATIONAHA.120.048740>
- Yoshida, Y., Simoes, E.J., 2019. Health Information Technologies in Diabetes Management. *Type 2 Diabetes* [Working Title]. <https://doi.org/10.5772/INTECHOPEN.83693>